{"id":"https://openalex.org/W7213558229","doi":"https://doi.org/10.3389/fonc.2026.1826735","title":"Managing skin-related adverse events during mirdametinib treatment for NF1-PNs: expert guidance from the ReNeu trial","display_name":"Managing skin-related adverse events during mirdametinib treatment for NF1-PNs: expert guidance from the ReNeu trial","publication_year":2026,"publication_date":"2026-09-18","ids":{"openalex":"https://openalex.org/W7213558229","doi":"https://doi.org/10.3389/fonc.2026.1826735","pmid":"https://pubmed.ncbi.nlm.nih.gov/42827732","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13631732"},"language":"en","primary_location":{"id":"doi:10.3389/fonc.2026.1826735","doi":"https://doi.org/10.3389/fonc.2026.1826735","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2026.1826735","pdf_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1826735/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1826735/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5036526586","display_name":"Angela C. Hirbe","orcid":"https://orcid.org/0000-0003-1719-0771","observed_orcids":["https://orcid.org/0000-0003-1719-0771"]},"institutions":[{"id":"https://openalex.org/I204465549","display_name":"Washington University in St. Louis","ror":"https://ror.org/01yc7t268","country_code":"US","type":"education","lineage":["https://openalex.org/I204465549"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Angela C. Hirbe","raw_affiliation_strings":["Washington University School of Medicine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Washington University School of Medicine","institution_ids":["https://openalex.org/I204465549"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044963977","display_name":"Milan J. Anadkat","orcid":"https://orcid.org/0000-0002-0723-3953","observed_orcids":["https://orcid.org/0000-0002-0723-3953"]},"institutions":[{"id":"https://openalex.org/I204465549","display_name":"Washington University in St. Louis","ror":"https://ror.org/01yc7t268","country_code":"US","type":"education","lineage":["https://openalex.org/I204465549"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Milan J. Anadkat","raw_affiliation_strings":["Washington University School of Medicine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Washington University School of Medicine","institution_ids":["https://openalex.org/I204465549"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031987164","display_name":"Christina L. Boull","orcid":"https://orcid.org/0000-0002-6393-4885","observed_orcids":["https://orcid.org/0000-0002-6393-4885"]},"institutions":[{"id":"https://openalex.org/I130238516","display_name":"University of Minnesota","ror":"https://ror.org/017zqws13","country_code":"US","type":"education","lineage":["https://openalex.org/I130238516"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christina L. Boull","raw_affiliation_strings":["University of Minnesota"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Minnesota","institution_ids":["https://openalex.org/I130238516"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091441085","display_name":"Christopher L. Moertel","orcid":"https://orcid.org/0000-0002-5474-588X","observed_orcids":["https://orcid.org/0000-0002-5474-588X"]},"institutions":[{"id":"https://openalex.org/I130238516","display_name":"University of Minnesota","ror":"https://ror.org/017zqws13","country_code":"US","type":"education","lineage":["https://openalex.org/I130238516"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher L. Moertel","raw_affiliation_strings":["University of Minnesota"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Minnesota","institution_ids":["https://openalex.org/I130238516"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021012894","display_name":"Molly Nickerson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405272447","display_name":"SpringWorks Therapeutics (United States)","ror":"https://ror.org/0466xvm69","country_code":"US","type":"company","lineage":["https://openalex.org/I4405272447"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Molly Nickerson","raw_affiliation_strings":["SpringWorks Therapeutics, Inc., a Healthcare Company of Merck KGaA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"SpringWorks Therapeutics, Inc., a Healthcare Company of Merck KGaA","institution_ids":["https://openalex.org/I4405272447"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034980594","display_name":"Michael Weber","orcid":"https://orcid.org/0000-0001-8007-9975","observed_orcids":["https://orcid.org/0000-0001-8007-9975"]},"institutions":[{"id":"https://openalex.org/I4405272447","display_name":"SpringWorks Therapeutics (United States)","ror":"https://ror.org/0466xvm69","country_code":"US","type":"company","lineage":["https://openalex.org/I4405272447"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael D. Weber","raw_affiliation_strings":["SpringWorks Therapeutics, Inc., a Healthcare Company of Merck KGaA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"SpringWorks Therapeutics, Inc., a Healthcare Company of Merck KGaA","institution_ids":["https://openalex.org/I4405272447"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069559198","display_name":"Dusica Babovic\u2010Vuksanovic","orcid":"https://orcid.org/0000-0001-6981-1352","observed_orcids":["https://orcid.org/0000-0001-6981-1352"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dusica Babovic-Vuksanovic","raw_affiliation_strings":["Mayo Clinic Rochester"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic Rochester","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5089918335","display_name":"Timothy R. Gershon","orcid":"https://orcid.org/0000-0001-7034-6400","observed_orcids":["https://orcid.org/0000-0001-7034-6400"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Timothy R. Gershon","raw_affiliation_strings":["Emory University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Emory University","institution_ids":["https://openalex.org/I150468666"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5036526586"],"corresponding_institution_ids":["https://openalex.org/I204465549"],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.55447861,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"16","issue":null,"first_page":"1826735","last_page":"1826735"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11173","display_name":"Neurofibromatosis and Schwannoma Cases","score":0.9355000257492065,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11173","display_name":"Neurofibromatosis and Schwannoma Cases","score":0.9355000257492065,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.055399999022483826,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mirdametinib","display_name":"mirdametinib","score":0.9929999709129333},{"id":"https://openalex.org/keywords/neurofibromatosis-type-1","display_name":"neurofibromatosis type 1","score":0.9769999980926514},{"id":"https://openalex.org/keywords/plexiform-neurofibroma","display_name":"plexiform neurofibroma","score":0.9520000219345093},{"id":"https://openalex.org/keywords/dermatologic-adverse-events","display_name":"dermatologic adverse events","score":0.9100000262260437},{"id":"https://openalex.org/keywords/mek-inhibitors","display_name":"MEK inhibitors","score":0.9430000185966492},{"id":"https://openalex.org/keywords/supportive-care","display_name":"supportive care","score":0.5860000252723694},{"id":"https://openalex.org/keywords/oncodermatology","display_name":"oncodermatology","score":0.703000009059906},{"id":"https://openalex.org/keywords/treatment-adherence","display_name":"medication adherence","score":0.6320000290870667},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.7110000252723694},{"id":"https://openalex.org/keywords/dose-adjustment","display_name":"dose adjustment","score":0.5479999780654907}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8751999735832214},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.7753000259399414},{"id":"https://openalex.org/C2778984943","wikidata":"https://www.wikidata.org/wiki/Q847605","display_name":"Neurofibromatosis","level":2,"score":0.6299999952316284},{"id":"https://openalex.org/C2780665704","wikidata":"https://www.wikidata.org/wiki/Q959298","display_name":"Intervention (counseling)","level":2,"score":0.5665000081062317},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5430999994277954},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.4652999937534332},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.43869999051094055},{"id":"https://openalex.org/C2780385302","wikidata":"https://www.wikidata.org/wiki/Q367158","display_name":"Protocol (science)","level":3,"score":0.41449999809265137},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.41100001335144043},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.37040001153945923},{"id":"https://openalex.org/C2993769353","wikidata":"https://www.wikidata.org/wiki/Q7598360","display_name":"Standard of care","level":2,"score":0.3433000147342682},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.3361000120639801},{"id":"https://openalex.org/C2989236134","wikidata":"https://www.wikidata.org/wiki/Q31207","display_name":"Patient care","level":2,"score":0.322299987077713},{"id":"https://openalex.org/C2778908642","wikidata":"https://www.wikidata.org/wiki/Q200779","display_name":"Genetic disorder","level":3,"score":0.30640000104904175},{"id":"https://openalex.org/C2779328685","wikidata":"https://www.wikidata.org/wiki/Q1475557","display_name":"Patient safety","level":3,"score":0.2786000072956085},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.2775000035762787},{"id":"https://openalex.org/C3018359032","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Safety profile","level":3,"score":0.2703000009059906},{"id":"https://openalex.org/C2777789703","wikidata":"https://www.wikidata.org/wiki/Q192102","display_name":"Skin cancer","level":3,"score":0.25920000672340393},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.25769999623298645},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.2542000114917755},{"id":"https://openalex.org/C163763905","wikidata":"https://www.wikidata.org/wiki/Q17075943","display_name":"Precision medicine","level":2,"score":0.25380000472068787}],"mesh":[],"locations_count":4,"locations":[{"id":"doi:10.3389/fonc.2026.1826735","doi":"https://doi.org/10.3389/fonc.2026.1826735","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2026.1826735","pdf_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1826735/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},{"id":"pmid:42827732","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42827732","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in oncology","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13631732","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13631732/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Front Oncol","raw_type":"Text"},{"id":"pmh:oai:doaj.org/article:fb46b6b0944046978eaf97ce5887b94a","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/fb46b6b0944046978eaf97ce5887b94a","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Oncology, Vol 16 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fonc.2026.1826735","doi":"https://doi.org/10.3389/fonc.2026.1826735","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2026.1826735","pdf_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1826735/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320311647","display_name":"Merck KGaA","ror":"https://ror.org/04b2dty93"},{"id":"https://openalex.org/F4320319694","display_name":"Springworks Therapeutics","ror":"https://ror.org/0466xvm69"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7213558229.pdf","grobid_xml":"https://content.openalex.org/works/W7213558229.grobid-xml"},"referenced_works_count":57,"referenced_works":["https://openalex.org/W1542229077","https://openalex.org/W1802213681","https://openalex.org/W1896328454","https://openalex.org/W1917720781","https://openalex.org/W1993668182","https://openalex.org/W2011513069","https://openalex.org/W2026440696","https://openalex.org/W2044090623","https://openalex.org/W2096046981","https://openalex.org/W2134758896","https://openalex.org/W2139663053","https://openalex.org/W2154748904","https://openalex.org/W2566164067","https://openalex.org/W2567378356","https://openalex.org/W2591172233","https://openalex.org/W2594529508","https://openalex.org/W2755008572","https://openalex.org/W2767049284","https://openalex.org/W2767910165","https://openalex.org/W2795876858","https://openalex.org/W2801815672","https://openalex.org/W2889624058","https://openalex.org/W2891214711","https://openalex.org/W2898897253","https://openalex.org/W2907791824","https://openalex.org/W2919781000","https://openalex.org/W2938213455","https://openalex.org/W2993024741","https://openalex.org/W3005192666","https://openalex.org/W3010907970","https://openalex.org/W3015043633","https://openalex.org/W3016227349","https://openalex.org/W3043280112","https://openalex.org/W3108145357","https://openalex.org/W3110893295","https://openalex.org/W3123814388","https://openalex.org/W3182858336","https://openalex.org/W3191915670","https://openalex.org/W4220744293","https://openalex.org/W4246883504","https://openalex.org/W4281919730","https://openalex.org/W4283827625","https://openalex.org/W4289203593","https://openalex.org/W4327596690","https://openalex.org/W4367297500","https://openalex.org/W4384563150","https://openalex.org/W4386745674","https://openalex.org/W4389886423","https://openalex.org/W4392986287","https://openalex.org/W4398228956","https://openalex.org/W4399592724","https://openalex.org/W4404173141","https://openalex.org/W4404196053","https://openalex.org/W4406104567","https://openalex.org/W4410872375","https://openalex.org/W7128250003","https://openalex.org/W7154597034"],"related_works":["https://openalex.org/W4404236914","https://openalex.org/W7156279877","https://openalex.org/W4409223065","https://openalex.org/W7165749531","https://openalex.org/W4404173141","https://openalex.org/W7134251202","https://openalex.org/W7135096145","https://openalex.org/W4400265569","https://openalex.org/W4416141228","https://openalex.org/W4416140580"],"abstract_inverted_index":{"Background:":[0],"Neurofibromatosis":[1],"type":[2],"1":[3],"(NF1)":[4],"is":[5,31],"a":[6,49,60,136],"genetic":[7],"disorder":[8],"in":[9,15,64,75,86,93,147,224],"which":[10],"plexiform":[11],"neurofibromas":[12],"(PNs)":[13],"develop":[14],"approximately":[16],"30%":[17],"to":[18,34,176],"50%":[19],"of":[20,28,77,81,117,161,181],"affected":[21],"individuals,":[22],"often":[23],"causing":[24],"substantial":[25,84],"morbidity.":[26],"Treatment":[27],"NF1-associated":[29],"PNs":[30],"challenging":[32],"due":[33],"disease":[35],"variability":[36],"and":[37,59,66,79,91,95,111,115,151,173,188,192],"tumor":[38,88],"complexity.":[39],"Observations:":[40],"In":[41],"the":[42,120,158,179],"Phase":[43],"2b":[44],"ReNeu":[45,121,143,206],"trial":[46,207],"(NCT03962543),":[47],"mirdametinib,":[48,110,132],"mitogen-activated":[50],"protein":[51],"kinase":[52,53],"1/2":[54],"(MEK)":[55],"inhibitor,":[56],"demonstrated":[57],"efficacy":[58],"manageable":[61],"safety":[62],"profile":[63],"children":[65,78],"adults":[67],"with":[68,83,106,131,149,220],"symptomatic":[69],"PNs,":[70],"achieving":[71],"confirmed":[72],"objective":[73],"responses":[74],"52%":[76],"41%":[80],"adults,":[82],"reductions":[85],"target":[87],"PN":[89],"volume":[90],"improvements":[92],"patient-":[94],"parent":[96],"proxy-reported":[97],"outcomes.":[98],"However,":[99],"dermatologic":[100],"adverse":[101],"events":[102],"(AEs)":[103],"are":[104],"common":[105],"MEK":[107,222],"inhibitors,":[108],"including":[109],"can":[112],"impact":[113],"adherence":[114],"quality":[116],"life.":[118],"While":[119],"protocol":[122],"included":[123],"supportive":[124],"care":[125],"considerations":[126],"for":[127,138,157,202,215],"skin":[128,163,183,217],"reactions":[129],"associated":[130,219],"some":[133],"investigators":[134],"recognized":[135],"need":[137],"more":[139],"detailed":[140],"guidance.":[141],"The":[142],"Scientific":[144],"Steering":[145],"Committee,":[146],"collaboration":[148],"oncology":[150],"oncodermatology":[152],"experts,":[153],"developed":[154,201],"expert-driven":[155],"recommendations":[156,198],"proactive":[159],"management":[160],"mirdametinib-related":[162,182],"AEs.":[164],"Conclusions:":[165],"These":[166],"strategies":[167],"emphasize":[168],"early":[169],"recognition,":[170],"individualized":[171],"care,":[172],"timely":[174],"intervention":[175],"help":[177],"reduce":[178],"severity":[180],"AEs,":[184],"minimize":[185],"dose":[186],"modifications,":[187],"support":[189],"treatment":[190,194],"continuity":[191],"long-term":[193],"goals.":[195],"Although":[196],"these":[197],"were":[199],"specifically":[200],"mirdametinib":[203],"based":[204],"on":[205],"experience,":[208],"they":[209],"may":[210],"also":[211],"provide":[212],"practical":[213],"guidance":[214],"managing":[216],"AEs":[218],"other":[221],"inhibitors":[223],"clinical":[225],"practice.":[226]},"counts_by_year":[],"updated_date":"2026-10-29T09:56:32.521200","created_date":"2026-09-18T00:00:00"}